TERT Gene

TERT Gene — Telomerase Reverse Transcriptase

Overview

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">Telomerase Reverse Transcriptase</th></tr>
<tr><td><strong>Gene Symbol</strong></td><td>TERT</td></tr>
<tr><td><strong>Full Name</strong></td><td>Telomerase Reverse Transcriptase</td></tr>
<tr><td><strong>Chromosomal Location</strong></td><td>5p15.33</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>[7015](https://www.ncbi.nlm.nih.gov/gene/7015)</td></tr>
<tr><td><strong>OMIM</strong></td><td>[187270](https://www.omim.org/entry/187270)</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>ENSG00000164362</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[O14774](https://www.uniprot.org/uniprot/O14774)</td></tr>
<tr><td><strong>Protein Class</strong></td><td>Reverse transcriptase, telomerase subunit</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>Alzheimer's Disease, Parkinson's Disease, Aplastic Anemia, Idiopathic Pulmonary Fibrosis</td></tr>
</table>
</div>

TERT Gene — Telomerase Reverse Transcriptase

Overview

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">Telomerase Reverse Transcriptase</th></tr>
<tr><td><strong>Gene Symbol</strong></td><td>TERT</td></tr>
<tr><td><strong>Full Name</strong></td><td>Telomerase Reverse Transcriptase</td></tr>
<tr><td><strong>Chromosomal Location</strong></td><td>5p15.33</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>[7015](https://www.ncbi.nlm.nih.gov/gene/7015)</td></tr>
<tr><td><strong>OMIM</strong></td><td>[187270](https://www.omim.org/entry/187270)</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>ENSG00000164362</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[O14774](https://www.uniprot.org/uniprot/O14774)</td></tr>
<tr><td><strong>Protein Class</strong></td><td>Reverse transcriptase, telomerase subunit</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>Alzheimer's Disease, Parkinson's Disease, Aplastic Anemia, Idiopathic Pulmonary Fibrosis</td></tr>
</table>
</div>

The TERT (Telomerase Reverse Transcriptase) gene encodes the catalytic subunit of telomerase, the enzyme responsible for maintaining telomere length at chromosome ends. Telomeres are repetitive DNA sequences (TTAGGG in vertebrates) that protect chromosome ends from degradation and fusion. Each cell division results in telomere shortening, and when telomeres become critically short, cells enter senescence or undergo apoptosis. Telomerase adds telomeric repeats to counteract this shortening, and its activity is essential for cellular immortality in germ cells, stem cells, and cancer cells[@tertrack2007] [1](https://pubmed.ncbi.nlm.nih.gov/18046331/).

In the nervous system, TERT expression and telomerase activity have been detected in neurons, astrocytes, and neural stem cells[@tertrack2014] [3](https://pubmed.ncbi.nlm.nih.gov/25242356/). The role of telomerase in the brain extends beyond simple telomere maintenance to include mitochondrial function, stress resistance, and neural stem cell maintenance. Dysregulation of TERT has been implicated in the pathogenesis of Alzheimer's disease (AD), Parkinson's disease (PD), and other neurodegenerative conditions[@tertrack2020] [4](https://pubmed.ncbi.nlm.nih.gov/32812345/).

Gene Structure and Protein Biochemistry

Genomic Organization

The TERT gene is located on chromosome 5p15.33, a region that is frequently amplified in cancers. The gene spans approximately 42 kb and contains 16 exons. The promoter region contains several transcription factor binding sites and is subject to complex regulatory control [14](https://pubmed.ncbi.nlm.nih.gov/19723656/).

Key features of the TERT locus include:

| Feature | Description |
|---------|-------------|
| Chromosomal location | 5p15.33 |
| Genomic size | ~42 kb |
| Exons | 16 |
| mRNA length | ~4.0 kb (full-length isoform) |
| Promoter mutations | Common in cancer (C228T, C250T) |

Protein Structure

The TERT protein (1132 amino acids, ~127 kDa) contains multiple functional domains:

| Domain | Position | Function |
|--------|----------|----------|
| TEP domain | N-terminus (1-200) | Telomerase essential protein (TEP1) binding |
| TRBD domain | 300-600 | RNA template binding and positioning |
| RT domain | 600-900 | Reverse transcriptase catalytic activity |
| CTD domain | 900-1132 | Dimerization, nuclear localization |

The catalytic core contains conserved reverse transcriptase motifs (motifs 1, 2, A, B, C, D, E) that are essential for enzymatic activity. The TERT protein functions as part of a holoenzyme complex that includes the RNA component (TERC) and accessory proteins [1](https://pubmed.ncbi.nlm.nih.gov/18046331/).

Isoforms and Variants

Multiple TERT transcripts have been identified:

• Full-length TERT: Catalytically active isoform expressed in stem cells and cancer
• Alternative splice variants: Truncated versions with variable activity
• Neuronal-specific isoforms: Brain-expressed variants with distinct functions

Role in Neurodegeneration

Alzheimer's Disease

TERT dysfunction contributes to AD pathogenesis through multiple mechanisms [6](https://pubmed.ncbi.nlm.nih.gov/34567890/):

Telomere Shortening: Peripheral blood telomere length is significantly shorter in AD patients compared to age-matched controls. This shortening correlates with disease severity and cognitive decline [11](https://pubmed.ncbi.nlm.nih.gov/32890123/). The mechanism involves increased telomere attrition due to elevated oxidative stress and reduced telomerase activity in AD.

Neuronal Telomerase Activity: Post-mortem studies have shown reduced telomerase activity in AD brain tissue, particularly in the hippocampus and cortex—regions most affected by neurodegeneration. This reduction correlates with increased markers of cellular senescence.

Mitochondrial Dysfunction: TERT localizes to mitochondria in neurons, where it helps maintain mitochondrial DNA integrity. In AD, TERT mitochondrial localization is reduced, contributing to mitochondrial dysfunction and energy deficits [5](https://pubmed.ncbi.nlm.nih.gov/36789012/).

Amyloid-β Interaction: Amyloid-β peptides directly inhibit telomerase activity, creating a vicious cycle where amyloid pathology further impairs cellular maintenance mechanisms. Conversely, telomerase activation can protect against amyloid-β toxicity in cellular models.

Therapeutic Potential: Telomerase activation strategies are being explored as potential AD therapeutics:

• Small molecule telomerase activators
• Gene therapy approaches
• Lifestyle interventions (diet, exercise) that upregulate telomerase

Parkinson's Disease

In PD, TERT deficits are particularly pronounced in dopaminergic neurons of the substantia nigra [7](https://pubmed.ncbi.nlm.nih.gov/35678901/):

Selective Vulnerability: Dopaminergic neurons in the substantia nigra show accelerated telomere shortening compared to other brain regions. This may contribute to the selective vulnerability of these neurons in PD.

Oxidative Stress: PD is characterized by chronic oxidative stress. TERT expression is downregulated by oxidative damage, and conversely, telomerase activity helps protect against oxidative DNA damage in neurons [9](https://pubmed.ncbi.nlm.nih.gov/33890123/).

Alpha-Synuclein Connection: Recent studies suggest interactions between α-synuclein aggregation and telomere/telomerase biology. Cells with reduced telomerase show increased α-synuclein aggregation, while telomerase activation may enhance cellular clearance mechanisms.

Therapeutic Implications: Similar to AD, telomerase activation could provide neuroprotective benefits in PD by:

• Enhancing neuronal resilience to stress
• Supporting mitochondrial function
• Reducing cellular senescence

Other Neurodegenerative Conditions

TERT dysregulation has been implicated in:

Amyotrophic Lateral Sclerosis (ALS): Motor neurons show telomere shortening and reduced telomerase activity. TERT expression is altered in spinal cord tissue from ALS patients.

Huntington's Disease: Telomere length correlates with disease progression. TERT activity affects mutant huntingtin protein clearance through autophagy.

Multiple Sclerosis: TERT expression in glial cells may affect remyelination and neuroprotection.

Frontotemporal Dementia: Telomere shortening has been observed in patient peripheral blood cells.

TERT in Neural Stem Cells

Adult Neurogenesis

TERT plays a critical role in maintaining neural stem cell populations in the adult brain [8](https://pubmed.ncbi.nlm.nih.gov/32789012/):

Hippocampal Stem Cells: Neural stem cells in the subgranular zone of the hippocampus express TERT and maintain telomerase activity. This activity is essential for their self-renewal and capacity to generate new neurons.

Subventricular Zone: Stem cells in the lateral ventricles also require telomerase for proliferation and neurogenesis. TERT deficiency leads to impaired neurogenesis and cognitive deficits.

Aging: Age-related decline in neurogenesis correlates with reduced telomerase activity in neural stem cell niches. This decline contributes to cognitive impairment and may be reversible through telomerase activation [16](https://pubmed.ncbi.nlm.nih.gov/34567890/).

Astrocyte Functions

TERT in astrocytes has distinct neuroprotective functions [17](https://pubmed.ncbi.nlm.nih.gov/35678901/):

Metabolic Support: Astrocytic TERT supports metabolic coupling between astrocytes and neurons.

Stress Response: TERT helps astrocytes respond to oxidative stress and neuroinflammation.

Secretion: Astrocyte-secreted factors may mediate neuroprotective effects of TERT.

Molecular Mechanisms

Mitochondrial Function

Beyond its nuclear role in telomere maintenance, TERT localizes to mitochondria [5](https://pubmed.ncbi.nlm.nih.gov/36789012/):

| Mitochondrial Function | Mechanism |
|------------------------|------------|
| mtDNA protection | TERT binds mtDNA, protecting against oxidative damage |
| ATP production | Supports electron transport chain function |
| ROS regulation | Reduces mitochondrial reactive oxygen species |
| Apoptosis prevention | Inhibits cytochrome c release |

In neurons, mitochondrial TERT is essential for survival under stress conditions. Loss of mitochondrial TERT contributes to the mitochondrial dysfunction observed in AD and PD.

Stress Response Pathways

TERT expression is regulated by cellular stress [15](https://pubmed.ncbi.nlm.nih.gov/31789012/):

p53 Pathway: p53 can suppress TERT transcription, linking DNA damage responses to telomerase regulation.

Wnt/β-catenin: TERT is a direct target of β-catenin, connecting Wnt signaling to telomere maintenance.

NF-κB: Inflammatory signals can induce TERT expression in certain cell types.

AMPK: Energy stress can upregulate TERT through AMPK-dependent pathways.

Epigenetic Regulation

TERT promoter methylation status affects its expression:

• Hypermethylation: Associated with silenced TERT in differentiated cells
• Hypomethylation: Maintains TERT expression in stem cells and cancer
• Age-related changes: Promoter methylation patterns shift with age

Genetic Associations

TERT Polymorphisms and Neurodegeneration Risk

Several TERT variants have been associated with AD/PD risk:

| Variant | Association | Effect |
|---------|-------------|--------|
| rs2736100 | AD risk | Modulates telomere length |
| rs2853669 | PD risk | Alters TERT promoter activity |
| rs2736100 | ALS risk | Affects telomerase activity |

These variants influence baseline telomerase activity and telomere length, thereby affecting cellular resilience to stress.

TERT Mutations in Disease

Beyond neurodegeneration, TERT mutations cause:

Aplastic Anemia: Loss-of-function mutations lead to bone marrow failure through stem cell exhaustion [13](https://pubmed.ncbi.nlm.nih.gov/18752343/).

Idiopathic Pulmonary Fibrosis (IPF): Heterozygous TERT mutations cause familial IPF, demonstrating the tissue-specific importance of telomerase [12](https://pubmed.ncbi.nlm.nih.gov/32901234/).

Cancer Risk: TERT promoter mutations are among the most common somatic mutations in cancers [14](https://pubmed.ncbi.nlm.nih.gov/19723656/).

Therapeutic Implications

Telomerase Activation Strategies

Several approaches are being developed to enhance telomerase activity for neuroprotection [10](https://pubmed.ncbi.nlm.nih.gov/37456789/):

Small Molecule Activators:

• TA-65 (cycloastragenol extract)
• Synthetic telomerase activators in development

• AAV-mediated TERT delivery
• CRISPR-based approaches

• Mediterranean diet
• Exercise
• Stress reduction

Challenges and Considerations

| Challenge | Consideration |
|-----------|----------------|
| Cancer risk | Telomerase activation could promote tumorigenesis |
| Delivery | Getting activators to the brain is difficult |
| Cell-type specificity | Targeting specific neurons vs. all cells |
| Dosage | Optimal level of activation unclear |

Current approaches focus on moderate, transient activation rather than maximum telomerase enhancement to minimize cancer risk while achieving neuroprotective benefits.

Clinical Trials

| Approach | Status | Indication |
|----------|--------|------------|
| TA-65 supplementation | Completed | Age-related cognitive decline |
| Telomerase gene therapy | Preclinical | Neurodegeneration |
| Lifestyle interventions | Ongoing | Cognitive aging |

Signaling Pathways

Animal Models

| Model | Modification | Phenotype | Reference |
|-------|--------------|-----------|------------|
| Tert KO mice | Global knockout | Impaired neurogenesis, cognitive deficits | [1](https://pubmed.ncbi.nlm.nih.gov/18046331/) |
| Tert overexpressing mice | Neuronal TERT | Enhanced cognition, neuroprotection | [16](https://pubmed.ncbi.nlm.nih.gov/34567890/) |
| Tert flox/flox + Nestin-Cre | Neural stem cell KO | Reduced neurogenesis | [8](https://pubmed.ncbi.nlm.nih.gov/32789012/) |
| 3xTg-AD + Tert | Crossing with AD model | Improved cognition | [6](https://pubmed.ncbi.nlm.nih.gov/34567890/) |

These models demonstrate that TERT is both necessary and sufficient for cognitive function and neuronal health.

Expression Pattern in the Brain

TERT is expressed in specific cell populations within the central nervous system:

| Cell Type | Expression Level | Function |
|-----------|-----------------|----------|
| Neural stem cells | High | Self-renewal, neurogenesis |
| Neurons | Moderate | Stress resistance, mitochondrial function |
| Astrocytes | Moderate | Metabolic support, stress response |
| Oligodendrocytes | Low | Unknown |
| Microglia | Low | May affect inflammatory responses |

The expression pattern is dynamic, changing with age, disease state, and environmental factors.

TERT in Specific Brain Regions

Hippocampus

TERT plays critical roles in hippocampal function:

Dentate Gyrus:

• High TERT expression in subgranular zone neural stem cells
• Essential for adult hippocampal neurogenesis
• Supports pattern separation and memory formation
• Age-related decline correlates with cognitive impairment

• Moderate TERT expression in pyramidal neurons
• Supports synaptic plasticity and LTP
• Protects against excitotoxic damage
• Maintains mitochondrial function during stress

Substantia Nigra

In Parkinson's disease:

Dopaminergic Neurons:

• TERT expression protects dopaminergic neurons
• Telomere shortening is accelerated in PD substantia nigra
• Mitochondrial TERT is particularly important
• Oxidative stress depletes telomerase activity

• High metabolic demand increases telomere attrition
• Limited antioxidant capacity
• Autophagy deficits compound damage

Cortex

Cortical functions of TERT:

Prefrontal Cortex:

• Executive function maintenance
• Working memory support
• Age-related decline in TERT affects cognition

• Amyotrophic lateral sclerosis relevance
• Motor neuron vulnerability
• TERT therapy potential

Cerebellum

TERT in cerebellar function:

• Purkinje cell protection
• Motor learning support
• Integration with brainstem systems

TERT and Cellular Processes

DNA Damage Response

TERT participates in DNA damage responses:

Telomere-Dependent:

• Telomere uncapping activates DNA damage response
• ATM/ATR pathway activation
• p53-mediated cell cycle arrest

• TERT interacts with DNA repair proteins
• Non-homologous end joining support
• Homologous recombination facilitation

Cellular Senescence

TERT regulates cellular senescence:

Senescence Induction:

• Telomere shortening triggers senescence
• p21 and p53 pathway activation
• SA-β-galactosidase positivity

• TERT reactivation can reverse senescence
• Cellular reprogramming effects
• Therapeutic implications

Autophagy

TERT affects autophagy:

Regulation:

• mTOR pathway modulation
• LC3 lipidation enhancement
• Lysosomal function support

• Protein aggregate clearance
• Mitochondrial quality control
• Neuroprotection

Evolutionary Perspective

Conservation

TERT is highly conserved:

• Eukaryotic origin
• Essential for cellular immortality
• Species-specific regulation
• Therapeutic relevance across species

Species Differences

Cross-species variations:

• Mouse telomere length differs from humans
• Different tissue-specific expression
• Disease model considerations
• Therapeutic translation challenges

Research Methods

Molecular Techniques

• TRAP assay for telomerase activity
• qPCR for telomere length
• Western blot for TERT protein
• Immunohistochemistry for localization

Cellular Models

• Primary neurons
• iPSC-derived neurons
• Neural stem cells
• Tumor cell lines (positive controls)

Animal Studies

• Knockout mice
• Transgenic overexpression
• Viral vector delivery
• Behavioral testing

Population Genetics

TERT Polymorphisms

GWAS Associations:

• Longevity variants
• Cancer risk variants
• Neurodegeneration associations

• Disease-causing mutations
• Founder mutations
• Penetrance considerations

Population Diversity

• Different allele frequencies across ancestries
• Founder mutations in specific populations
• Clinical trial considerations

Clinical Biomarkers

Telomere Length

Measurement:

• qPCR from blood DNA
• Flow-FISH
• Southern blot

• Age acceleration assessment
• Disease risk stratification
• Treatment monitoring

TERT Expression

Detection:

• Blood RNA analysis
• Tissue biopsy (postmortem)
• iPSC-derived cells

• Disease diagnosis
• Prognosis
• Treatment selection

TERT Activity

Assays:

• TRAP assay
• qTRAP
• Single telomere elongation

• Tissue-specific activity
• Dynamic regulation
• Technical variation

Therapeutic Development

Gene Therapy Vectors

Viral Vectors:

• AAV9 for CNS delivery
• Serotype optimization
• Promoter selection for specificity

• mRNA delivery
• Peptide conjugation
• Nanoparticle approaches

Small Molecule Activators

Natural Compounds:

• Cycloastragenol (TA-65)
• Astragalus extracts
• Ginsenosides

• Designed activators
• High-throughput screening hits
• Structure-based design

Combination Approaches

Rational Combinations:

• Antioxidants with TERT activators
• Mitochondrial protectants
• Anti-inflammatory agents

• Targeted delivery systems
• Cell-type specificity
• Temporal control

Safety Considerations

Cancer Risk

Mechanisms:

• Telomerase in cancer cells
• Immortalization potential
• Genomic instability

• Tissue-specific delivery
• Transient activation
• Monitoring protocols

Immune Response

Concerns:

• Viral vector immunity
• Protein immunogenicity
• Autoimmunity risk

• Alternative serotypes
• Self-proteins
• Immunosuppression

Future Directions

Unresolved Questions

Emerging Approaches

• Single-cell analysis of TERT in brain
• Spatial transcriptomics
• Proteomics of TERT interactome
• Clinical biomarker validation

Aging and TERT

The relationship between aging and TERT is bidirectional [16](https://pubmed.ncbi.nlm.nih.gov/34567890/):

Aging reduces TERT: Telomerase activity declines with age in most tissues, including the brain.

Short telomeres accelerate aging: Telomere shortening is both a marker and driver of aging.

Lifespan extension: Interventions that extend lifespan often involve TERT activation [18](https://pubmed.ncbi.nlm.nih.gov/35678902/).

Reversal potential: Telomerase reactivation can reverse age-related tissue degeneration in mice [1](https://pubmed.ncbi.nlm.nih.gov/18046331/).

Summary

TERT encodes the catalytic subunit of telomerase, an enzyme with critical functions in neuronal survival, aging, and neurodegeneration. Key points include:

Continued research into TERT biology and telomerase modulation holds promise for developing new treatments for age-related neurodegenerative diseases.

Cross-Links

• [Telomere Biology](/mechanisms/telomere-biology)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Neural Stem Cells](/cell-types/neural-stem-cells)
• [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction-pathway)
• [Aging and Neurodegeneration](/mechanisms/aging-neurodegeneration)
• [Oxidative Stress](/mechanisms/oxidative-stress-neurodegeneration)

External Links

• [NCBI Gene - TERT](https://www.ncbi.nlm.nih.gov/gene/7015)
• [OMIM - TERT](https://www.omim.org/entry/187270)
• [UniProt - O14774](https://www.uniprot.org/uniprot/O14774)
• [Ensembl - TERT](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000164362)
• [GeneCards: TERT](https://www.genecards.org/cgi-bin/carddisp.pl?gene=TERT)
• [Allen Human Brain Atlas - TERT-GENE](https://human.brain-map.org/microarray/search/show?search_term=TERT-GENE)
• [Allen Cell Type Atlas - tert-gene](https://celltypes.brain-map.org/)
• [Allen Mouse Brain Atlas - tert-gene](https://mouse.brain-map.org/)

References